SNORA71A is aberrantly expressed in various cancers; for example, it is upregulated in colorectal, gallbladder, breast and non-small cell lung cancer, where it enhances proliferation, migration, invasion and drug resistance of malignant cells through targeting different signaling pathways (NF-kappa B, Toll-like receptor, Jak-STAT, AKT/NRF2/GPX4, TGF-β, MAPK/ERK, etc.)[59,60,61,62]. Here, GPX4 is linked to cancer.